Waste Management (WM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waste Management (WM) concluded the recent trading session at $229.45, signifying a -1.57% move from its prior day's close.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
WM rides on strong infrastructure and acquisitions for steady growth, but high debt, liquidity strain and modest momentum may temper investor enthusiasm.
The latest trading day saw Waste Management (WM) settling at $229.96, representing a +2.18% change from its previous close.
Waste Management's revenue grew 7.1% to $6.31 billion in its most recently reported quarter. The company's full-year adjusted operating EBITDA margin exceeded 30% for the first time last year.
Brown Brothers Harriman and Co. cut its position in Waste Management, Inc. (NYSE: WM) by 1.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,674,477 shares of the business services provider's stock after selling 27,651 shares during the quarter.
In the most recent trading session, Waste Management (WM) closed at $235.54, indicating a -4.45% shift from the previous trading day.
WM shares outpace the industry in a month as its waste services network, renewable energy expansion and Stericycle integration support steady growth.
Waste Management (WM) reported earnings 30 days ago. What's next for the stock?
Waste Management is downgraded from buy to hold due to a stretched valuation near a 32x P/E, above its 5-year average. Despite Q4's double miss, WM delivered robust year-over-year EPS and revenue growth, expanded margins, and accelerated free cash flow. Management projects strong 2026 growth with FCF of $3.75–$3.85B, a $3B buyback, and a 14.5% dividend hike.
Waste Management maintains resilience, despite revenue deceleration, with strong margin expansion and robust cash flow supporting a reiterated buy rating. Their Healthcare Solutions segment delivered 53% YoY revenue growth, validating management's strategic diversification amid legacy business sluggishness. Efficiency improvements drove Q4 adjusted EBITDA margin to 31.3%, up 240 bps YoY, and supported 14% adjusted EPS growth, despite macro headwinds.